

28-01-2022

The Assistant Manager-Surveillance,
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai-400051
Symbol: THYROCARE

Sir,

Sub: Increase in price/volume of our equity shares.

With reference to your letter No. NSE/CM/Surveillance/11609 dated 27-01-2022 sent to us by mail, we wish to reply as follows:

1. We have been disclosing all the information / particulars as per the provisions of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.
2. There are no price sensitive information /details which have not been disclosed and which may have an impact on the price/volume of the shares traded on the exchanges.
3. Moreover, in the last couple of weeks, there has been significant volatility observed on the NSE/BSE across various scrips, due to the factors beyond control /knowledge and we have not come across any reasoning to justify / explain in particular the volatility observed in the case of Thyrocare scrip.

The movement in price/volume of the shares is purely market driven. We request you to kindly take our above reply on your records.

Yours faithfully,


Ramjee Dorai

Company Secretary & Compliance Officer



Thyrocare Technologies Limited